Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul;18(7):1212–1220. doi: 10.1016/j.hrthm.2021.03.016

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Heart Rhythm Society.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Dronedarone causes greater inhibition of cardiac action potential amplitude (APA) and upstroke velocity at more positive resting membrane potentials (RMPs). A: Data from human-induced pluripotent stem cells–derived cardiac myocytes (hiPSC-CMs) demonstrating the effect of resting membrane potential/holding potential (RMP/V_H) on sodium current (I_Na) inhibition by flecainide (1 μM; N = 7 cells), propafenone (300 nM; N = 8 cells) and dronedarone (5 μM; N = 7 cells). B: RMP/V_H sensitivities of flecainide, propafenone, and dronedarone. ∗∗P <.01, 1-way analysis of variance (ANOVA) with Bonferroni post hoc analysis. C: Action potentials (APs) measured at 3 different RMPs (–100, –90, and –70 mV) measured in a single hiPSC-CM ± dronedarone (5 μM), paced at 1 Hz. D, E: Mean data from hiPSC-CMs (N = 7 cells). Data are given as mean ± SEM, 1-way repeated measures ANOVA.